BL 1020

Drug Profile

BL 1020

Alternative Names: AN-168; BL-1020; CYP-1020; Perphenazine GABA ester; Perphenazine-4-aminobutyrate

Latest Information Update: 18 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bar-Ilan University; Tel Aviv University
  • Developer BioLineRx
  • Class Antipsychotics; Esters; Phenothiazines; Piperidines; Small molecules
  • Mechanism of Action Dopamine receptor antagonists; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Schizoaffective disorder; Schizophrenia

Most Recent Events

  • 18 Mar 2014 Discontinued - Phase-II for Schizoaffective disorder in Israel (PO)
  • 18 Mar 2014 Discontinued - Phase-II for Schizoaffective disorder in Romania (PO)
  • 18 Mar 2014 Discontinued - Phase-II for Schizophrenia in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top